22nd Century Group Enters CBD Health and Wellness Market with Investment in Panacea Life Sciences, Inc. Investment provides platform to commercialize 22nd Century’s unique hemp/cannabis plant lines in development...
After beginning the year with a 57.4% gain in Q1, the Global Cannabis Stock Index moved sharply lower again in November, its eighth consecutive monthly decline, as it lost 12.0% to...
After a 57.4% gain in Q1 followed by a pullback that had left it down 1% year-to-date as of the end of August, the Global Cannabis Stock Index moved sharply lower...
After a 57.4% gain in Q1 followed by a 28.0% pullback in Q2 and 13.8% decline in July, Cannabis stocks, as measured by the Global Cannabis Stock Index, moved sharply...
After a 57.4% rebound in Q1, Cannabis stocks, as measured by the Global Cannabis Stock Index, gave up some ground in April, declining 1.5%: The index, which had 64 qualifying...
Cannabis stocks, as measured by the Global Cannabis Stock Index, extended their 2019 gains in March, increasing 2.2% to 100.76, leaving the index up 57.4% so far this year: The...
Cannabis stocks, as measured by the Global Cannabis Stock Index, bounced back sharply from Q4 losses of 44.2%, rallying 44.2% in January to 92.33: The index, which had 43 qualifying...
Cannabis stocks, as measured by the Global Cannabis Stock Index, extended the declines from mid-October, declining 10.0% to 80.32 in November: The index, which has 61 qualifying members after the...
SILVER SPRING, Md., Oct. 3, 2018 /PRNewswire/ — 4Front Holdings, LLC (“4Front”), a leading retail and brand development company in the U.S. cannabis sector, today announced plans to open...
Cannabis stocks, as measured by the Global Cannabis Stock Index, fell again in June, declining 4.5% to 100.12, after going into the final week of the month with a small gain: The...
Horizons Medical Marijuana Life Sciences ETF (TSX: HMMJ) (OTC: HMLSF), the world’s first and still only cannabis ETF, has adjusted its portfolio this month as its benchmark, the North...
22nd Century Launches Major New Initiative to Produce Medically-Important Marijuana Cannabinoids 22nd Century is only U.S. firm able to operate freely in the cannabinoid biosynthetic pathway; Company intends to...